$NEOV

NeoVolta and SK On sign a five-year deal expected to support up to 18 gigawatt-hours

NeoVolta (NEOV) and SK On signed a five-year deal for up to 18 GWh of LFP battery cells and BESS packs. SK On will supply 9 GWh of U.S.-made cells to NeoVolta, with an option for another 9 GWh. The agreement supports NeoVolta's Pendergrass, Georgia, expansion, targeting 8 GWh of annual BESS capacity by 2028.

Original reporting
Published Aug 31, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 12:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$NEOV
Bullish
high confidence
Mentioned
$NEOV
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$NEOVBullishMed
01

Why it matters

The deal secures a reliable LFP cell supply, enabling NeoVolta to increase production capacity and capture growing demand for domestic energy storage solutions.

02

Market read

The partnership is a material corporate development for NeoVolta, likely to influence its stock price and the broader U.S. battery storage market.

03

What to watch

The agreement hinges on SK On's ability to deliver U.S.-manufactured cells at competitive prices; supply constraints could delay expansion.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

NeoVolta (NASDAQ: NEOV) is a U.S. energy storage company expanding its BESS manufacturing platform in Georgia.

Company-level read

Ticker impact

$NEOVBullishHigh confidence
Context

NeoVolta announced a five-year supply and manufacturing collaboration with SK On for up to 18 GWh of LFP battery cells, driving a 1.9% price rise.

Expected impact

Potential upside of 5‑10% over the next 3‑6 months if capacity ramps as planned.

Evidence & confidence

New multi‑year contract with a major supplier, sizable volume, and immediate market reaction indicate material upside.

Market effects

Strengthens the U.S. LFP battery and BESS sector, signaling increased domestic supply chain activity.

Boosts Georgia's manufacturing outlook and may attract further energy storage projects in the U.S.

Highlights SK On's push into the U.S. market, potentially influencing global LFP cell pricing.

Counterpoint

If NeoVolta fails to scale production, the partnership could become a cost burden without delivering expected revenue.

Key entities

  • NeoVolta Inc.

    U.S. energy storage provider, ticker NEOV.

  • SK On

    South Korean battery manufacturer partnering with NeoVolta.

Related articles

$NEOVMed

NeoVolta Announces Strategic U.S. Battery Cell Supply And BESS Manufacturing Collaboration With SK On

NeoVolta Inc. (NEOV) announced a five-year collaboration with SK On, securing 9 GWh of U.S.-made LFP battery cells from 2027 to 2031. The deal includes an additional 9 GWh cell supply and pack purchase arrangement, totaling 18 GWh. NeoVolta Power will produce energy storage packs for SK On, supporting NeoVolta's Pendergrass production expansion and strategic U.S. manufacturing platform.

$LMTMed

New Pentagon Deal Expands Production of Next-Gen Missiles

The Pentagon and Lockheed Martin agreed to expand production of the AIM-260 missile, a next-gen air-to-air weapon. Lockheed Martin claims it offers greater range and effectiveness. The deal includes funding for increased production capacity. Australia also plans to acquire the missile, investing $736 million.

$METAMed

Meta Just Launched a New Subscription Business Built Entirely Around AI. Here's Why It Could Be a Game-Changer.

Meta Platforms (META) launched Meta One, a subscription service offering expanded AI features across Facebook, Instagram, and WhatsApp. Plans range from $7.99 to $499 per month. The move aims to diversify revenue as Meta faces high AI infrastructure costs and relies heavily on advertising. Meta's Q2 revenue rose 28% to $60.8B, but net income fell 15%. Analysts expect Q3 revenue of $73.66B.

$BIIBMedAI 8/10

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M

Biogen Inc. (BIIB) reported that EMPAVELI (pegcetacoplan) showed a 75% relative reduction in proteinuria in adolescents with C3G or primary IC-MPGN in a Phase 3 study. The FDA recently expanded EMPAVELI's label to include reducing kidney function loss in patients aged 12 and older. The drug is the only approved treatment for these conditions in adolescents, according to the company.

$XPEVMed

XPeng's New Flagship SUV Costs 231,800 Yuan, and the Industry's Old Price Logic Is Gone

XPeng launched its new flagship SUV, the G9L, priced at 231,800 yuan, undercutting industry expectations. The company claims the vehicle includes over 100 features from its 500,000-yuan class models as standard. XPeng CEO He Xiaopeng also mentioned talks with other carmakers, including German ones, for technology and chip sharing. The aggressive pricing reflects intense competition in China's EV market, with margins being squeezed.